We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

AGILENT

  Silver Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Dolichol Biomarker Evaluated for Congenital Disorders of Glycosylation

By LabMedica International staff writers
Posted on 14 Aug 2020
Print article
The AB MDS SCIEX API4000 tandem mass spectrometer (Photo courtesy of SCIEX).
The AB MDS SCIEX API4000 tandem mass spectrometer (Photo courtesy of SCIEX).
A congenital disorder of glycosylation (CDG; previously called carbohydrate-deficient glycoprotein syndrome) is one of several rare inborn errors of metabolism in which glycosylation of a variety of tissue proteins and/or lipids is deficient or defective.

CDG often cause serious, sometimes fatal, malfunction of several different organ systems (especially the nervous system, muscles, and intestines) in affected infants. Dolichol is a membrane lipid which carries monosaccharides and glycans for N-linked protein glycosylation occurring in the endoplasmic reticulum.

Scientists from the Charles University and General University Hospital (Prague, Czech Republic) analyzed urine samples from 75 controls, six patients with CDG ((NUS1-CDG, SRD5A3-CDG, two with PMM2-CDG, PGM1-CDG, DPAGT1-CDG), and 43 patients with suspicion of CDG. Furthermore, tissue homogenates (frontal cortex, skeletal muscle, heart and liver) from two NUS1-CDG patients and two controls (at the age 0–5 years) were also analyzed. The dolichol ratio determination was established as a non-invasive screening method and evaluated through a screening for rare CDG syndromes.

The urine and tissue samples were processed and homogenized with a 4710 Series Ultrasonic Homogenizer, (Cole Parmer, Vernon Hills, IL, USA). The dolichols (Dol) were analyzed by using the AB MDS SCIEX API4000 tandem mass spectrometer (Applied Biosystems, Foster City, CA, USA) coupled with Agilent 1290 Infinity UPLC System (Agilent Technologies, Santa Clara, CA, USA).

The dolichol 18 to dolichol 19 (Dol18/Dol19) ratio biomarker was compared in urine samples with different CDGs to evaluate its use for identifying these disorders. The investigators reported that in the control group, a significant correlation between the ratio of Dol18/Dol19 and age was found in urine. They established a reference range for Dol18/Dol19 from the urine samples. The ratio of Dol18/Dol19 was significantly higher in both urine and tissue samples from patients with mutation in NUS1 in comparison to controls.

The authors concluded that their results on test samples show a novel diagnostic option for patients with rare congenital disorders of glycosylation, especially for those with pathological mutations in NUS1, who cannot be detected by usual screening methods. The study was published in the August, 2020 issue of the journal Clinica Chimica Acta.


Related Links:

Charles University and General University Hospital
Cole Parmer
Applied Biosystems
Agilent Technologies
Gold Supplier
Fluorimetric Immunoassay Analyzer
Confiscope F20
New
Silver Supplier
Immunochromatographic Analyzer
INCLIX S700
New
High-Speed Centrifuge
HIMAC CR22N
New
Cytology Sample Processor
SDSCP9000 CytoPath Processor

Print article

Channels

Molecular Diagnostics

view channel
Image: Model of the PD-1 (Programmed cell death protein 1) protein. Only a subset of recurrent glioblastomas respond to anti-PD-1 immunotherapy (Photo courtesy of Wikimedia Commons)

Biomarker Predicts Potential Benefit of Checkpoint Inhibitor Therapy for Brain Cancer Patients

A phosphorylated form of ERK (extracellular signal-regulated kinase) protein has been identified as a biomarker that may be used to predict which brain cancer patients might benefit from checkpoint inhibitor... Read more

Hematology

view channel
Image: The UniCel DxH 800 Coulter Cellular Analysis System (Photo courtesy of Beckman Coulter)

Monocyte Distribution Width Predicts Sepsis in Critically Ill Patients

Sepsis has been reported as a major cause of increased morbidity, length of stay and mortality among patients hospitalized in Intensive Care Units (ICUs) for any cause. The survival of patients developing... Read more

Immunology

view channel
Image: Procartaplex Immunoassays Kits are based on the principles of a sandwich ELISA, using two highly specific antibodies binding to different epitopes of one protein to quantitate all protein targets simultaneously (Photo courtesy of Thermo Fisher Scientific)

Assay Developed for Patient-Specific Monitoring and Treatment for Ovarian Cancer

Tumors can influence peripheral immune macroenvironment, thereby creating opportunities for non-invasive serum/plasma immunobiomarkers for immunostratification and immunotherapy designing.... Read more

Microbiology

view channel
Image: Clinical metagenomics (CMg) using nanopore sequencing (Photo courtesy of Oxford Nanopore Technologies)

Same Day Test Identifies Secondary Infections in COVID-19 Patients

The intensive care unit (ICU) is a dynamic environment with frequent staff-patient contact for invasive monitoring, interventions and personal care that together introduce the risk of secondary or nosocomial... Read more

Pathology

view channel
Image: The Ventana BenchMark Ultra autostainer is for cancer diagnostics with automation and the test menu include IHC, ISH, and FITC tests (Photo courtesy of Ventana Medical System)

Specific Biomarker Investigated for Triple-Negative Breast Cancer Diagnosis

Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression and comprises a heterogeneous... Read more

Technology

view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more

Industry

view channel
Illustration

Global HBA1c Laboratory Tests Market Driven by Rise in Diabetic Population

The global HBA1c laboratory tests market is projected to expand at a significant pace over the coming years, driven by an increase in the prevalence of diabetes, rise in prescription rate of HBA1c tests... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.